<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597140</url>
  </required_header>
  <id_info>
    <org_study_id>ChungAng</org_study_id>
    <nct_id>NCT02597140</nct_id>
  </id_info>
  <brief_title>Pilot Study of Effect of Intravenous Lidocaine on Propofol Requirement in Facial Plastic Surgery</brief_title>
  <official_title>Pilot Study of Effect of Intravenous Lidocaine on Propofol Requirement During Monitored Anesthesia Care in Facial Plastic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized pilot study is to evaluate the effect of intravenous lidocaine
      on propofol requirement during BIS (Bispectral index) guided MAC (monitored anesthesia care)
      in facial plastic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies reported the usefulness of intravenous lidocaine as a coadjuvant agent during
      general anesthesia. We thought that there would be an interaction between intravenous
      lidocaine and hypnotic agent requirement. However, there is no data regarding the effect of
      systemic lidocaine during MAC. We, thus, would like to perform a randomized, double-blinded
      pilot study to evaluate the effect of intravenous lidocaine on propofol requirement during
      BIS guided MAC in facial plastic surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total propofol requirements</measure>
    <time_frame>during monitored anesthesia care</time_frame>
    <description>Patients' sedation depth will be monitored using a BIS monitor. Propofol will be administered using target controlled infusion (TCI) from targeting 60 to 80 of BIS. At the end of surgery, total propofol requirements will be examined and collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>30 minutes, 2 hours, and 4 hours after surgery</time_frame>
    <description>The outcome assessor will evaluate the degree of postoperative pain using a numeric rating scale (NRS). (0 = no pain, 10 = unimaginable severe pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anesthesia, Intravenous; Surgery, Plastic</condition>
  <arm_group>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous normal saline infusion of 2 mg/kg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.</description>
    <arm_group_label>Lidocaine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>0.9% saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.</description>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Presofol MCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical status classification 1 or 2 patients

          -  aged 20-65 years who were undergoing elective facial plastic surgery under monitored
             anesthesia care

        Exclusion Criteria:

          -  unwillingness to participate in the study

          -  adverse reaction to the drugs used in the study

          -  use of medications that interfere in local anesthetic metabolism

          -  history of liver disease or kidney failure

          -  neurological or psychiatric disease

          -  history of drug or alcohol abuse

          -  chronic use of benzodiazepine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Geun Joo Choi, MD, PhD</last_name>
    <phone>+82-2-6299-3166</phone>
    <email>geunjoo.choi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chongwha Baek, MD, PhD</last_name>
    <phone>+82-2-6299-2583</phone>
    <email>nbjhwa@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Deok Kim, MD, PhD</last_name>
      <phone>82-2-6299-2571</phone>
      <email>ksdeok@cau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Chongwha Baek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geun Joo Choi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>November 5, 2015</last_update_submitted>
  <last_update_submitted_qc>November 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</investigator_affiliation>
    <investigator_full_name>Chongwha Baek</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

